Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation
Michele Fornaro1, Matteo Martino1, Florinda Battaglia2, Salvatore Colicchio3, Giulio Perugi41Department of Neuroscience, Section of Psychiatry, University of Genova, Genoa, Italy; 2Center of Excellence for Biomedical Research (CEBR), Genoa, Italy; 3Department of Neurosciences, Catholic University, R...
Guardado en:
Autores principales: | Michele Fornaro, Matteo Martino, Florinda Battaglia, et al |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/594b8dfc3c07494fbd367fa94a91453f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy and Safety of Cordyceps militaris as an Adjuvant to Duloxetine in the Treatment of Insomnia in Patients With Depression: A 6-Week Double- Blind, Randomized, Placebo-Controlled Trial
por: Jiaojiao Zhou, et al.
Publicado: (2021) -
Tinnitus psychopharmacology: A comprehensive review of its pathomechanisms and management
por: Michele Fornaro, et al.
Publicado: (2010) -
Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study
por: Jean-Pierre Olié, et al.
Publicado: (2010) -
The role of duloxetine in the treatment of anxiety disorders
por: Domenico De Berardis, et al.
Publicado: (2008) -
Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder
por: Nagao K, et al.
Publicado: (2013)